Loading search results
Sponsor study identifier
Secondary identifiers
observational
89
1 country
1
Study Start
May 27, 2009
Actual (reported)Primary Completion
January 11, 2023
Actual (reported)Study Completion
January 11, 2023
Actual (reported)This study (https://pdrisk.ninds.nih.gov) will determine if people who have risk factors for Parkinson disease (PD) have biomarkers (objective ways to measure a disease process) that show that the disease process is actually going on, and if people who have abnormal biomarkers go on to develop PD during several years of follow-up. Biomarkers of Parkinson disease (PD) might identify people who are healthy now but may develop the disease later in life. Healthy volunteers and people who have certain risk factors for developing PD who are between 18 and 70 years of age may be eligible for this study. People with the following risk factors are included:
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 11, 2023
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 17, 2008
Actual (reported)October 20, 2008
Actual (reported)May 27, 2009
Actual (reported)January 11, 2023
Actual (reported)January 11, 2023
Actual (reported)Parkinson Disease Diagnosed
The primary objective of this study is to determine whether among people at increased statistical risk for developing PD those with clinical laboratory biomarkers of central or cardiac catecholamine deficiency are diagnosed with PD during follow-up, whereas those without evidence of central or peripheral catecholamine deficiency are not diagnosed with PD during follow-up.
annually within 7.5 years
Individuals who may be at risk for developing PD because of genetic risk, olfactory dysfunction, symptomatic rapid eye movement sleep behavior disorder, or orthostatic hypotension
The subjects are individuals who may be at risk for developing PD, because of (a) genetic risk i.e., a family history of PD or genotypic abnormalities known to be associated statistically with PD; (b) olfactory dysfunction i.e., decreased ability to distinguish among odors; (c) symptomatic rapid eye movement (REM) sleep behavior disorder (RBD); or (d) orthostatic hypotension.
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Goldstein DS, Holmes C, Sullivan P, Lopez G, Gelsomino J, Moore S, Isonaka R, Wu T, Sharabi Y. Cardiac noradrenergic deficiency revealed by 18F-dopamine positron emission tomography identifies preclinical central Lewy body diseases. J Clin Invest. 2024 Jan 2;134(1):e172460. doi: 10.1172/JCI172460.
David S Goldstein, M.D.
National Institute of Neurological Disorders and Stroke (NINDS)
89 participants (actual enrollment reported by the registry).
First Submitted
October 17, 2008
First Posted
October 20, 2008
Study Start
May 27, 2009
Actual (reported)Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
January 11, 2023
Actual (reported)Study Completion
January 11, 2023
Actual (reported)Last Updated
September 19, 2025
Record last verified: 2025-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: